共 42 条
- [41] Longitudinal BCVA analysis of low- or high -dose MCO-010 mutation agnostic optogenetic therapy for retinitis pigmentosa: 12-month results from a Phase 2b/3 randomized, sham controlled, patient- and assessor masked clinical trial (RESTORE) INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
- [42] Longitudinal Analysis of BCVA and Near-Field Object Recognition in Low- or High-Dose MCO-010 Mutation Agnostic Optogenetic Therapy for Retinitis Pigmentosa: 12-Month Results from a Phase 2b/3 Randomized, Sham-Controlled, Patient- and Assessor-Masked Clinical Trial (RESTORE) MOLECULAR THERAPY, 2024, 32 (04) : 451 - 451